This record is sourced from an Exhibit 99.1 press release furnished with Intersect ENT's Form 8-K filed May 13, 2022, announcing the completed closing of the acquisition rather than its original signing.
Perella Weinberg Partners LP served as financial advisor to Medtronic, the acquirer, per the release's statement that "The Medtronic financial advisor for the transaction is Perella Weinberg Partners LP, with Ropes & Gray LLP acting as legal advisor." Goldman Sachs & Co. LLC served as financial advisor to Intersect ENT, the target, as stated in "Intersect ENT's financial advisor is Goldman Sachs & Co. LLC, with Cooley LLP acting as legal advisor." No lead designation is specified for either side since each company retained a single financial advisor.
On the legal side, Ropes & Gray LLP represented Medtronic and Cooley LLP represented Intersect ENT.
The release describes the strategic rationale (expanding Medtronic's chronic rhinosinusitis treatment portfolio) and notes that Intersect ENT employees joined Medtronic as part of the closing, but it does not describe the consideration structure (cash, stock, or mix) in this particular exhibit.
Not disclosed in the sourced document is the transaction's purchase price or valuation multiple, the original August 2021 signing date's financial terms, or any regulatory conditions that were satisfied prior to this closing announcement.